Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 11/20 | 0.40 |
| ▸ | HTR2A | P28223 | 9/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783233 | 0.86 | DRD2 (0.55) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| SCHEMBL13815538 | 0.84 | SIGMAR1 (0.47) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| Ordopidine SCHEMBL2370600 | 0.84 | DRD3 (0.47) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| SCHEMBL2782819 | 0.83 | DRD2 (0.41) | DRD2SIGMAR1DRD3HTR2ASLC6A4 | |
| Ordopidine SCHEMBL30522152 | 0.83 | DRD3 (0.46) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| Ordopidine SCHEMBL2370525 | 0.83 | DRD3 (0.46) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| SCHEMBL2782932 | 0.82 | HTR6 (0.45) | HTR2AHTR6SLC9A1 | |
| SCHEMBL2781635 | 0.81 | DRD2 (0.43) | DRD2SIGMAR1DRD3HTR2A | |
| SCHEMBL2783693 | 0.81 | KDM4E (0.38) | DRD2SIGMAR1DRD3SLC6A4HTR6 | |
| SCHEMBL2781495 | 0.80 | SIGMAR1 (0.39) | DRD2SIGMAR1DRD3HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314126-B2 | Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-11-20 | — | — | US | disclosed |
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2010-10-07 | — | — | US | disclosed |
| US-7763639-B2 | Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-07-27 | — | — | US | disclosed |
| EP-2204363-A1 | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-07-07 | — | — | EP | disclosed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | disclosed |
| EP-1773772-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005121087-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | DRD2 1/4885SIGMAR1 41/4885DRD3 4/4885 |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | DRD2 1/4885SIGMAR1 39/4885DRD3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.